Alkermes Amends Credit Agreement to Lower Borrowing Costs
I'm LongbridgeAI, I can summarize articles.Alkermes amended its credit agreement with JPMorgan Chase and other lenders to reduce borrowing costs. The amendment lowered interest rate spreads by 0.75 percentage points for Term Loan A and 0.50 percentage points for Term Loan B. This adjustment aims to improve financing terms and support long-term capital management. The company's stock currently holds a 'Buy' rating from analysts with a $65 price target, while AI analysis rates it as Neutral due to mixed financial metrics.
Alkermes ( (ALKS) ) has provided an update.
On August 12, 2026, Alkermes plc amended a credit agreement originally signed on February 12, 2026 with JPMorgan Chase Bank, BofA Securities and other lenders, covering its senior secured term loan A and term loan B facilities. The term loan A balance stands at about $745.3 million and matures on February 12, 2031, while the term loan B totals about $773.1 million and matures on August 12, 2031.
The amendment cut the interest rate spread on the term loan A facility by 0.75 percentage point and on the term loan B facility by 0.50 percentage point, lowering Alkermes’ borrowing costs. Following the change, the loans will bear interest based on Term SOFR or an alternate base rate plus reduced margins linked to the company’s secured net leverage, which should improve its financing terms and support its long‑term capital management.
The most recent analyst rating on (ALKS) stock is a Buy
with a $65.00 price target.
To see the full list of analyst forecasts on Alkermes stock,
see the ALKS Stock Forecast page.
Spark’s Take on ALKS Stock
According to Spark, TipRanks’ AI Analyst, ALKS is a Neutral.
The score is driven primarily by a mixed financial profile: profitability has weakened sharply in the latest TTM and leverage rose materially, even though free cash flow remains positive. Technicals are moderately supportive longer-term (above key medium/long moving averages) but weaker near-term (below the 20-day). Valuation is a key drag due to the very high P/E, partially offset by a generally constructive earnings call featuring strong sales momentum and maintained guidance alongside acknowledged margin and cost pressures.
To see Spark’s full report on ALKS stock,
click here.
More about Alkermes
Alkermes plc is a biopharmaceutical company that develops and commercializes medicines, with operations organized through entities including Alkermes, Inc. and Alkermes Finance LLC. The group uses senior secured term loan facilities arranged by major U.S. banks to support its financing needs and capital structure, reflecting an active approach to managing its debt profile.
The company’s credit arrangements include a term loan A facility and a term loan B facility, both senior secured and syndicated among multiple lenders. These facilities have staggered maturities in 2031 and are benchmarked to rates such as Term SOFR and an alternate base rate, with margins tied in part to the company’s secured net leverage ratio.
Average Trading Volume: 2,142,516
Technical Sentiment Signal: Buy
Current Market Cap: $8.29B